AbbVie (NYSE: ABBV) Wins European Regulator Backing for MAVIRET in Acute Hepatitis C

AbbVie announced a positive Committee for Medicinal Products (CHMP) opinion for MAVIRET (glecaprevir/pibrentasvir) to treat acute hepatitis C infection, clearing a key regulatory hurdle in Europe. The CHMP recommendation paves the way toward European Commission approval, expanding the approved uses of the existing antiviral therapy.

By the Numbers

• CHMP positive opinion issued for acute hepatitis C indication
• Stock traded at $219.53 on Friday, May 22, up 2.35% from the previous close of $214.50
• MAVIRET already approved for chronic hepatitis C treatment, now under review for acute cases

Why It Matters

The CHMP recommendation is a regulatory win that validates MAVIRET's clinical profile beyond chronic infection. If approved by the European Commission, the expanded indication could open a new patient population and drive incremental revenue from acute hepatitis C cases, which represent an unmet treatment need in Europe.

AbbVie's pipeline breadth across infectious disease remains central to offsetting revenue pressure in other therapeutic areas. A positive CHMP opinion strengthens the company's regulatory momentum heading into the second half of 2026.

Investor Takeaway

The CHMP recommendation reduces regulatory risk for this label expansion. European Commission approval is likely but not certain; investors should monitor the timeline. Success here demonstrates ongoing clinical validation of MAVIRET and adds a new revenue stream to AbbVie's marketed portfolio.